Therapeutic Asset Ratings
4,361 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Cyclophosphamide
Advanced Solid Tumor
National Cancer Institute (NCI)
P3
B
(62)
Docetaxel
Head And Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
P3
B
(62)
Entinostat
Breast Carcinoma
National Cancer Institute (NCI)
P3
B
(62)
Epoetin Alfa
Acute Myeloid Leukemia
National Cancer Institute (NCI)
P3
B
(62)
Fludarabine
B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
P3
B
(62)
Nivolumab
Bone Metastases
National Cancer Institute (NCI)
P3
B
(62)
TAMOXIFEN
Breast Adenocarcinoma
National Cancer Institute (NCI)
P3
B
(62)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Melanoma
National Cancer Institute (NCI)
P2
B
(62)
Atezolizumab
Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
P2
B
(62)
Azacitidine
Acute Megakaryoblastic Leukemia In Adult
National Cancer Institute (NCI)
P2
B
(62)
Azacitidine
Adult Pure Erythroid Leukemia
National Cancer Institute (NCI)
P2
B
(62)
AZD1775
Refractory Malignant Neoplasm
National Cancer Institute (NCI)
P2
B
(62)
Bet Bromodomain Inhibitor Zen-3694
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(62)
Bortezomib
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
National Cancer Institute (NCI)
P2
B
(62)
cd22 car-transduced t cells
B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
P2
B
(62)
Cediranib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(62)
Cyclophosphamide
Hematopoietic And Lymphoid Cell Neoplasm
National Cancer Institute (NCI)
P2
B
(62)
Durvalumab
Recurrent Fallopian Tube Carcinoma
National Cancer Institute (NCI)
P2
B
(62)
Eloxatin
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
B
(62)
Fludarabine
Therapy-Related Myeloid Neoplasm
National Cancer Institute (NCI)
P2
B
(62)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Breast Cancer
National Cancer Institute (NCI)
P2
B
(62)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Fallopian Tube Carcinoma
National Cancer Institute (NCI)
P2
B
(62)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
Primary Peritoneal Carcinoma
National Cancer Institute (NCI)
P2
B
(62)
Ipilimumab
Ovarian Carcinoma
National Cancer Institute (NCI)
P2
B
(62)
Irinotecan
Adenosquamous Cell Lung Cancer
National Cancer Institute (NCI)
P2
B
(62)
Showing 551 to 575 of 4,361 assets
Previous
Page 23 of 175
Next